Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology

ABUS•2026-07-16

Arbutus cites prior Moderna settlement

Arbutus received USD 178 million from Moderna under a March 2026 settlement over LNP patents.

Share repurchase plans tied to Genevant dividend

Arbutus plans up to about USD 230 million in share repurchases starting in Q3 2026, contingent on a Genevant-related dividend.

Patent suits target Pfizer and BioNTech over LNP technology

Roivant unit Genevant joined Arbutus in filing patent infringement suits against Pfizer, BioNTech over lipid nanoparticle technology used in mRNA COVID-19 vaccines.

Actions target patents including Canadian Patent No. 2,721,333, EP 4 241 767, EP 4 495 237, seeking damages and injunctions.

Sources

Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology

Publicnow

Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology

Arbutus cites prior Moderna settlement

Share repurchase plans tied to Genevant dividend

Patent suits target Pfizer and BioNTech over LNP technology

Related News

Qube Research & Technologies discloses net short position in DBV Technologies

Nasdaq trade halt <NVVE.O> volatility trading pause at 09:41 AM

Xometry Inc <XMTR.O>: Wedbush assumes coverage with outperform rating; target price $126

Sources

Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology

EBAY: Wedbush Assumes Coverage With Outperform Rating; Target Price $135

US Stocks-S&P 500, Nasdaq set for lower open as chip weakness weighs